



Dr. Massimo Pancione

- **Actual Positions:** Confirmed Researcher at the Department of Sciences and Technologies, Scientific Sector: BIO-11, University of Sannio, Via Port'Arsa, 11, 82100 Benevento, Italy;
- Staff Researcher at Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, University Complutense, Madrid, Spain.
- **Scientific activity:** 40 papers published, total SCI citation over 600, H-index of 15.

TEL: 0039 0824 305157, Mobile 3511161887

FAX: 0039 0824 305147

E mail: massimo.pancione@unisannio.it; or pancione.massimo@gmail.com

ACCADEMIC EDUCATION

- 1995-2000: B.Sc. in Biochemistry and Molecular Biology at the (University of Sannio, and University of Naples, Naples, Federico II, Italy)
- 2001-2013: Post graduate Training at CNR, Institute of food science, Avellino, Italy and Clinical pathology laboratory, Fatebenefratelli Hospital, Benevento, Italy
- 2004-2009: PhD in Life Sciences, (University of Sannio, Benevento, Italy)
- 2010-2013: Researcher of Molecular Biology (University of Sannio, Benevento, Italy)
- 2015-2017: Staff Scientist at the Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, Madrid, Spain
- 2013-today: Confirmed Researcher (University of Sannio, Benevento, Italy)

ACADEMIC COMMITTEES AND INSTITUTIONAL ACTIVITIES

- 2011-present: Teaching activities in Molecular Biology, member examination committee and responsibilities in the practical lab sessions included designing laboratory course program and content. Teaching Supervisor for the final examination Degree (1st Level) in Biotechnology and Master Degree (2nd Level) in Biology.
- 2013-present: Board member committee assignments thesis and practical activities lab sessions, Department of Sciences and Technologies University of Sannio, Benevento, Italy

SCIENTIFIC ACTIVITIES AND CONFERENCES

- **The main research interest concerns: a) The role of centrosome linker in health and diseases; b) Identification of novel biomarkers of the tumor microenvironment as therapeutic targets; c) The role of tumor microenvironment in cancer development and drug resistance.**
- Author of over 35 publications in scientific journal concerning basic cancer research
- Prizes: Santa Cruz best paper prize 2013
- 2015-present: Editorial Board Member of Scientific Reports (NPG), Gastroenterology Research and practice (Hindawi)
- 2014-present: member of scientific society euroscicon, controlling cancer summit; Italian society of Cancerology
- Invited speaker in the following congresses:
 - a) Control cancer summit 2013-2015 London, UK
 - b) BIT's annual Congress of MolMed 2013-2015
 - c) Emirates Surgical Pathology Conference 2014-2015
 - d) International Conference & Exhibition on Pathology 2014-2015
 - e) BIT's 8th Annual World Cancer Congress Korea-2014-2015

EDITORIAL AND REVIEW ACTIVITIES

BMC cancer; Oncogene (Nature Group); Journal of Translational Medicine; Gastroenterology Research and Practice; PLOSone; World Journal of Gastroenterology; Scientific Reports (Nature Group); Human Pathology, British Journal of Cancer (Nature Group), Open Biology.

SCIENTIFIC COLLABORATIONS

Departments of Surgery, Medical Oncology and Pathology of the "Fatebenefratelli" Hospital, Benevento, Italy; Departments of Oncology and Anatomic Pathology Rummo Hospital, Benevento, Italy; Department of Diagnostic and Pathology, Faculty of Medicine, University of Verona; Department of Biotechnology, Faculty of Science, University of Verona, Italy; II University of Naples, Department of General Pathology, Naples, Italy; Center for Oncology Research "Pascale Institute" Naples, Italy; Department of Pathology, Konkuk University School of Medicine, Seoul, Korea; Department of Pathology, University of Athens, School of Medicine, Attikon University Hospital, Athens, Greece; National Centre of Pathology, Vilnius University Santariskiu Clinics Affiliate. Lithuania; Institute of Pathology, University Hospital Erlangen, Erlangen, Germany; Department of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University, Madrid, Spain. Dr. Elmar Schiebel, Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Allianz, Heidelberg, Germany.

PRINCIPAL INVESTIGATOR FOR THE FOLLOWING RESEARCH PROJECT:

- Identification of novel therapeutic target of the tumor microenvironment (Roche Pharmaceuticals, 2013)
- DNA hypo/hypermethylation in cancer: decrypt the epigenetic basis of the paradox. (Epigen, 2011).
- Identification of novel genes causing colonic rhabdoid tumors.
- Role of immune cells and inflammatory response in aggressive cancers.
- "Progettazione, sintesi e studi Biologici di farmaci innovativi verso importanti target nella terapia del cancro" (PRIN MIUR 2012)
- Prize by for research production (MIUR, 2017)

TEACHING ACTIVITY

- 2011-present: Teaching activities in Molecular Biology, member examination committee and responsibilities in the practical lab sessions included designing laboratory course program and content. (n.12 CFU).
- 2011-present: Teaching Supervisor for the final examination Degree (1st Level) in Biotechnology and Master Degree (2nd Level) in Biology.

OTHER ACTIVITIES

- 2012-present: Coordinator, lecturer and member examination committee, in the course of Molecular Biology with laboratory which is integral part of the course Degree (1st Level) in Biotechnology, Department of Sciences and Technologies University of Sannio, Benevento, Italy.
- 2013-present: Board member committee assignments thesis and practical activities lab sessions, Department of Sciences and Technologies University of Sannio, Benevento, Italy
- 2014-present: Member committee to design schedule quality assurance of the Department of Sciences and Technologies “SUA-CdS” to ensure an acceptable standards of educational programmes and infrastructure according to the regulations of the Italian Ministry of Education.
- 2015-2018 Reviewer for Czech Health Research Council.
- 2017-today Council Member of the *Gerson Lehrman Group (GLG)*

Publications

1. **Pancione M**, N Forte, L Sabatino, E Tomaselli, D Parente, A Febbraro, V Colantuoni. Reduced β -catenin and PPAR γ expression levels are associated to colorectal cancer metastatic progression: correlation with TAMs, COX-2 and patients' outcome: *Human PATHOLOGY* 2009; 40:714-25.
2. D Capaccio, A Ciccodicola, L Sabatino, A Casamassimi, **M Pancione**, A Fucci, A Febbraro, A Merlino, G Graziano, V Colantuoni. A novel germline mutation in Peroxisome Proliferator-Activated Receptor γ gene associated with large intestine polyp formation and dyslipidemia. *Biochimica et Biophysica Acta (BBA)/Molecular Basis of disease* 2010; 1802:572-581.
3. **Pancione M**, N Forte, A Fucci, L Sabatino, A Febbraro, A Di Blasi, B Daniele, D Parente, V Colantuoni. Prognostic role of β -catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. *Human PATHOLOGY* 2010; 41:867-876.
4. **Pancione M**, N Forte, S Campione, A Napolitano, D Parente, L Sabatino, A Febbraro, V Colantuoni. The high expression of p53 in sporadic colorectal carcinoma is associated with metastasis and decreased survival. *PATHOLOGICA* 2010;102:51-56.
5. Persico, M; **Pancione, M**; Fucci, A.; Sabatino, L.; Pasquali, D.; Masarone, M.; La Mura, V.; Persico, E.; Vecchione, R.; Colantuoni, V. Hepatic Retinol Binding Protein 4 (Rbp-4) Levels Are Significantly Related To The Steatohepatitis Grade (Compromission) But Not With Hcv Infection. *Digestive and Liver Disease* vol. 42 February, 2010. p. S49 (published as Abstract)
6. **Pancione M**, A Di Blasi, L Sabatino, A Fucci, AM Dalena, N Palombi, P Carotenuto, B Daniele, N Normanno, V Colantuoni. A novel case of rhabdoid colon carcinoma associated with a CIMP+ phenotype and *BRAF* mutation. *Human PATHOLOGY*. 2011;42:1047-52
7. D Pasquali, L Circelli, A Faggiano, **Pancione M**, A Renzullo, R Elisei, C Romei, G Accardo, VR Coppola, M De Palma, F Grimaldi, P Ferolla, A Colao, V Colantuoni. *CDKN1B* V109G Polymorphism a New Prognostic Factor in Sporadic Medullary Thyroid Carcinoma. *European Journal of Endocrinology*. 2011;164:397-404
8. L Sabatino, A Fucci, **Pancione M**, V Carafa, A Nebbioso, C Pistore, F Babbio, C Votino, C Laudanna, M Ceccarelli, L Altucci, IM Bonapace, V Colantuoni. UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG) epigenetic silencing and mediates colorectal cancer progression. *Oncogene* 2012 Dec 6;31(49):5061-72.
9. **Pancione M**, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. *Patholog Res Int*. 2012;2012:509348.

10. Sabatino L, Fucci A, **Pancione M**, Colantuoni V. PPAR γ Epigenetic Deregulation and Its Role in Colorectal Tumorigenesis. *PPAR Res.* 2012;2012:687492.
11. Fucci A, Colangelo T, Votino C, **Pancione M**, Sabatino L, Colantuoni V. The role of peroxisome proliferator-activated receptors in the esophageal, gastric, and colorectal cancer. *PPAR Res.* 2012;2012:242498.
12. Remo A, **Pancione M**, Zanella C, Vendraminelli R. Molecular Pathology of Colorectal Carcinoma. A systematic review centred on the new role of Pathologist. *Pathologica* 2012.
13. **Pancione M**, A Remo, L Sabatino, C Votino , A Fucci , C Zanella , A Di Blasi, G Lepore, B Daniele, F Femizia, N Normanno, R Vendraminelli, E Manfrin, V Colantuoni. Right-sided rhabdoid colorectal tumors might be related to the Serrated Pathway; *Diagnostic Pathology* 2013 Feb 20;8:31
14. Remo A, Zanella C, **Pancione M**, Astatì L, Piacentini P, Cingarlini S, Bonetti SA, Micheletto C, Talamini A, Chilosi M, Vendraminelli R, manfrin E. Lung metastasis from TTF-1 positive sigmoid adenocarcinoma. Pitfalls and management. *Pathologica* 2013.
15. Colangelo T, Fucci A, Votino C, Sabatino L, **Pancione M**, Laudanna C, Binaschi M, Bigioni M, Maggi CA, Parente D, Forte N, Colantuoni V. MicroRNA-130b promotes tumour progression and is associated with poor prognosis in colorectal cancer. *Neoplasia* 2013 Oct; 15(10): 1218-31.
16. **Pancione M**, Remo A, Zanella C, Sabatino L, Di Blasi A, Dalena AM, Laudanna C, Astatì L, Rocco M, Delfina B, Piacentini P, Pavan L, Purgato A, Greco F, Talamini A, Bonetti A, Ceccarelli M, Vendraminelli R, Manfrin E, Colantuoni V. The chromatin remodeling component SMARCB1/INI1 influences aggressive behavior of colorectal cancer through a gene signature mapping to chromosome 22. *Journal of Translational Medicine.* 2013 Nov 28; 11:297; 2013
17. Sabatino L, **Pancione M**, Votino C, Colangelo T, Lupo A, Novellino E, Lavecchia A and Colantuoni V. The emerging role of the β -catenin-PPAR γ axis in the pathogenesis of colorectal cancer. *World Journal of Gastroenterology* 2013. In press
18. Pagnotta SM, Laudanna C, **Pancione M**, Sabatino L, Votino C, Remo A, Cerulo L, Zoppoli P, Manfrin E, Colantuoni V and Ceccarelli M. Ensemble of Gene Signatures Reveals Novel Biomarkers in Colon Cancer through PPAR γ and TNF Signaling. *PLoSone* 2013 Aug 19;8(8): e72638.
19. Ferrara G, **Pancione M**, Votino C, Quaglino P; Tomasini M, Santucci M, Pimpinelli M, Sabatino L, Colantuoni V. A specific DNA methylation profile correlates with a high risk of disease progression in stage I classical (Alibert-Bazin type) mycosis fungoides. *British Journal of Dermatology*, November 1, 2013.
20. **Pancione M**, Giordano G, Remo A, Febbraro A, Sabatino L, Manfrin E, , Ceccarelli M, Colantuoni V. Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis. *Clinical and Developmental Immunology. Journal of Immunology Research.* Volume 2014, Article ID 686879, 2013
21. Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, **Pancione M**. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. *Gastroenterol Res Pract.* 2014;2014:526178. doi: 10.1155/2014/526178.
22. Manfrin E, Remo A, **Pancione M**, Cannizzaro C, Falsirollo F, Brunelli M, Pollini GP, Pellini F, Molino A, Vendraminelli R, Ceccarelli M, Pagnotta SM, Simeone I, Bonetti F. Comparison between Invasive breast cancer with extensive peritumoral vascular invasion and Inflammatory breast carcinoma. A clinical pathological study of 161 cases. *American Journal of Clinical Pathology* 2014. In press
23. Piepoli A, Panza A, Votino C, Gentile A; Valvano MR, Colangelo T, **Pancione M**, Merla G, Andriulli A, Sabatino L, Vinciguerra M, Mazzoccoli G, Colantuoni V. Peroxisome Proliferator-Activated Receptor gamma-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer. *BBA - Molecular Cell Research* 2014.
24. Giordano G, Febbraro A, Tomaselli E, Sarnicola ML, Parcesepe P, Parente D, Forte N, Fabozzi A, Remo A, Bonetti A, Manfrin E, Ghasemi S, Ceccarelli M, Cerulo L, Bazzoni F, **Pancione M**. Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. *J Exp Clin Cancer Res.* 2015 Oct 1;34(1):108.
25. Remo A, **Pancione M**, Zanella C, Manfrin E p16 Expression in Prostate Cancer and Nonmalignant Lesions: Novel Findings and Review of the Literature. *Appl Immunohistochem Mol Morphol.* 2015 Apr 21.
26. Remo A, Simeone I, **Pancione M**, Parcesepe P, Finetti P, Cerulo L, Bensmail H, Birnbaum D, Van Laere SJ, Colantuoni V, Bonetti F, Bertucci F, Manfrin E, Ceccarelli M. Systems biology analysis reveals NFAT5 as a novel biomarker and master regulator of inflammatory breast cancer. *J Transl Med.* 2015 May 1;13:138. doi: 10.1186/s12967-015-0492-2.
27. Parcesepe P, Sina S, Zanella C, **Pancione M**, Giuliani J, Detogni P, Curti P, Bonetti A, Manfrin E, Remo A. Case Report of a Well-Differentiated Papillary Mesothelioma of the Tunica Vaginalis in an Undescended Testis With Review of Literature. *Int J Surg Pathol.* 2016 Aug;24(5):443-7. doi: 10.1177/1066896916628279. Epub 2016 Feb 12. Review
28. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, Fucci A, Milone MR, Budillon A, Santopaolo M, Votino C, **Pancione M**, Piepoli A, Mazzoccoli G, Binaschi M, Bigioni M, Maggi CA, Fassan M, Laudanna C, Matarese G, Sabatino L, Colantuoni V. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. *Cell Death Dis.* 2016 Feb 25;7:e2120. doi: 10.1038/cddis.2016.28.
29. Parcesepe P, Giordano G, Laudanna C, Febbraro A, **Pancione M**. Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. *Gastroenterol Res Pract.* 2016;2016:6261721. doi: 10.1155/2016/6261721. Epub 2016 Feb 23. Review.

30. Giordano G, Spagnuolo A, Olivieri N, Corbo C, Campagna A, Spagnoletti I, Pennacchio RM, Campidoglio S, **Pancione M**, Palladino L, Villari B, Febbraro A. Cancer drug related cardiotoxicity during breast cancer treatment. *Expert Opin Drug Saf*. 2016 Aug;15(8):1063-74. doi: 10.1080/14740338.2016.1182493. Epub 2016 Jul 6. Review
31. Votino C, Laudanna C, Parcesepe P, Giordano G, Remo A, Manfrin E, **Pancione M** Aberrant BLM cytoplasmic expression associates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer. *J Gastroenterol*. 2017 Mar;52(3):327-340. doi: 10.1007/s00535-016-1222-0. Epub 2016 May 11.
32. **Pancione M**, Giordano G, Parcesepe P, Cerulo L, Coppola L, Curatolo AD, Conciatori F, Milella M, Porrás A. Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer. *Curr Med Chem*. 2017 Feb 27. doi:10.2174/0929867324666170227114356. [Epub ahead of print]
33. Remo A, Grillo F, Mastracci L, Fassan M, Sina S, Zanella C, Parcesepe P, Damiano Urso E, **Pancione M**, Bortuzzo G, Scarpa A, Manfrin E. Clear cell colorectal carcinoma: Time to clarify diagnosis. *Pathol Res Pract*. 2017 May;213(5):447-452. doi:10.1016/j.prp.2017.02.013. Epub 2017 Feb 24
34. Giordano G, **Pancione M**, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D'Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. *World J Gastroenterol*. 2017 Aug 28;23(32):5875-5886.
35. Remo A, Manfrin E, Parcesepe P, Ferrarini A, Han HS, Mickys U, Laudanna C, Simbolo M, Malanga D, Oliveira DM, Baritono E, Colangelo T, Sabatino L, Giuliani J, Molinari E, Garonzi M, Xumerle L, Delledonne M, Giordano G, Ghimenton C, Lonardo F, D'angelo F, Grillo F, Mastracci L, Viglietto G, Ceccarelli M, Colantuoni V, Scarpa A, **Pancione M**. Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers. *Mol Cancer Res*. 2018 Sep;16(9):1385-1395. doi: 10.1158/1541-7786.MCR-18-0062. Epub 2018 May 21.
36. Parcesepe P, Giordano G, Zanella C, Giuliani J, Greco F, Bonetti A, **Pancione M**, Manfrin E, Molinari E, Latiano TP, D'Andrea MR, Fassan M, Olivieri N, Remo A. Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report. *Pathol Res Pract*. 2019 Feb;215(2):387-391. doi: 10.1016/j.prp.2018.11.021. Epub 2018 Nov 29.
37. Giordano G, Olivieri N, D'Andrea MR, Di Raimo T, Manfrin E, Remo A, **Pancione M**, Brunelli M, De Santis E, Coppola G, Scarpa A, Coppola L, Parcesepe P. Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report. *Oncol Lett*. 2019 Jan;17(1):462-467. doi: 10.3892/ol.2018.9579. Epub 2018 Oct 15.
38. Giordano G, Parcesepe P, D'Andrea MR, Coppola L, Di Raimo T, Remo A, Manfrin E, Fiorini C, Scarpa A, Amoreo CA, Conciatori F, Milella M, Caruso FP, Cerulo L, Porrás A, **Pancione M**. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer. *J Exp Clin Cancer Res*. 2019 Jan 22;38(1):28. doi: 10.1186/s13046-018-1019-5.
39. Remo A, Cecchini MP, Benati D, Bernardi P, Manfrin E, Giordano G, Bonomi F, Parcesepe P, Fassan M, Colombari R, Sbarbati A, **Pancione M**. CROCC-mutated rhabdoid colorectal carcinoma showing in intercellular spaces lamellipodia and cellular projections revealed by electron microscopy. *Virchows Arch*. 2019 Mar 10. doi: 10.1007/s00428-019-02554-4. [Epub ahead of print]

May 21, 2019

Dr. Massimo Pancione

Massimo Pancione